LLS Community is a project of the Michael J. Garil Data Collective

We are a community of blood cancer patients, survivors and caregivers. We’re here to support you, give you trusted information and resources, and help you feel connected. No one should have to face a blood cancer diagnosis alone.

x

Articles > Myeloma

  1. FDA APPROVES NOVEL CAR T-IMMUNOTHERAPY FOR THE TREATMENT OF MULTIPLE MYELOMA

    Chimeric Antigen Receptor (CAR) T cell-therapy is on a roll. Today marks the seventh approval of CAR T therapy since the first approval in 2017. While all prior approvals with CAR T have directed the engineered T-cells to CD19, a marker on the surface of malignancies derived from B-cells, this is the first approval of a B-cell maturation antigen (BCMA)-directed CAR T. Idecabtegene vicleucel or ide-cel (Abecma) is the first approval of a CAR T for multiple myeloma. This approval comes on the h...

    Read More

  1. NEW DRUG APPROVAL EXPANDS OPTIONS FOR PATIENTS WITH TRIPLE-CLASS REFRACTORY MULTIPLE MYELOMA

    Rye Brook, N.Y. (February 26, 2021) – The U.S. Food and Drug Administration (FDA) today announced approval of melphalan flufenamide, also known as melflufen (Pepaxto), in combination with dexamethasone for the treatment of adults with multiple myeloma whose disease has returned or worsened following prior treatment with four different classes of drugs. Today’s approval of melflufen was based on results from HORIZON, a pivotal phase 2 study. Melflufen demonstrated a 23.7% overall respon...

    Read More

  2. FDA Approves New Therapy for Patients with Previously Treated Multiple Myeloma

    Some promising news as Myeloma Awareness Month kicks off: the U.S. Food and Drug Administration (FDA) approved today a new therapy for patients with relapsed/refractory multiple myeloma. The approval provides an important new treatment option for patients with difficult-to-treat multiple myeloma. The new therapy, called isatuximab (Sarclisa®), is approved in combination with pomalidomide and dexamethasone for the treatment of adults with multiple myeloma who have received at least two pri...

    Read More

  3. More Progress in Cancer Research at #ASCO18

    Chicago is once again the site of the annual American Society of Clinical Oncology Meeting (#ASCO18), where more than 30,000 scientists, advocates and representatives from the biopharmaceutical industry have gathered to share the their latest clinical findings and to learn from each other in education sessions, scientific presentations and opportunities for networking. The meeting began Friday and continues through Tuesday. The field of cancer science is moving so rapidly and it’s ex...

    Read More

  1. Achieving the Impossible: What’s ahead in 2018?

    We’ve just concluded one of the most historic years on record in terms of new therapy approvals for blood cancers. In all, the U.S. Food and Drug Administration (FDA) approved 18 therapies to treat patients with blood cancers, including some entirely new agents and some new uses for already approved drugs. Among these approvals were the first new therapies – four to be precise – for acute myeloid leukemia (AML) after a 40-year drought in treatment advances for this deadly blood c...

    Read More

  2. Lodging & Transportation Resources for Cancer Survivors

    By Margaret Martin, RD, MS, LDN, Licensed Dietitian and Nutritionist; Certified Diabetes Educator, PearlPoint Cancer Support As part of cancer treatment, you may make frequent trips to your cancer treatment center for appointments and treatment. If your treatment center isn’t close to home, this may mean extra transportation and lodging expenses. Many resources are available to cancer patients to help cover the costs of travel for treatment. The first step is to talk to your healt...

    Read More

  3. What is Medicare?

    By Abby Henry, Oncology Content Manager, PearlPoint Cancer Support Medicare is an insurance program run by the United States government. Medicare is for people who 65 years or older Under 65 but have received Social Security Disability Insurance (SSDI) for 24 months Have end-stage renal disease or Amyotrophic Lateral Sclerosis (ALS) Medicare has 4 types of possible coverage. Part A (Hospital Insurance): Part A covers inpatient care such as hospital care, nursin...

    Read More

  4. Is Your Food Safe?

    By Margaret Martin, RD, MS, LDN, Licensed Dietitian and Nutritionist; Certified Diabetes Educator, PearlPoint Cancer Support Food safety is a valuable goal year-round but especially in the warmer months. Why? More people travel and transport food during the vacation months. The outside temperatures in summer and early autumn often leave outdoor food in the danger zone, between 40 degrees and 140 degrees. Food eaten at outdoor events like picnics, tailgates, and cookouts are at a higher...

    Read More

  5. Am I Depressed?

    Do you ever feel sad, withdrawn, or blue? Did these feelings appear or become more pronounced after your or your loved one’s diagnosis? If so, you are not alone. Many patients and caregivers report feeling down during the course of a cancer journey. These feelings can arise when adjusting to a new diagnosis or changes in relationships. They can also arise while adjusting to life after treatment or living as a “survivor”, even many years later. Identity challenges or emotions such as gui...

    Read More

  6. Caregiver Spotlight: Using Writing to Heal and Cope

    Caregiving can cause a roller coaster of emotions that change over time. Finding time and outlets to cope is not always easy. Dr. Robert Winn, medical director of Deer Valley and The Canyons in Park City, knows this struggle all too well. Life was near perfect for Dr. Winn and his beloved wife Nancy. When Nancy was diagnosed with acute myeloid leukemia (AML), their world went tumbling out of control. Dr. Winn could not speak of Nancy's illness without getting choked up or crying, so to commun...

    Read More